Making the biotech IPO work

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Capital investment and end valuations for each technology class.

References

  1. 1

    Foster, R.N. Innovation: The Attacker's Advantage (Summit Books, New York; 1986).

  2. 2

    Christensen, C.M. & Raynor, M.E. The Innovator's Solution: Creating and Sustaining Successful Growth (Harvard Business School Press, Boston; 2003).

  3. 3

    McNamee, L.M. & Ledley, F.D. Nat. Biotechnol. 30, 937–943 (2012).

  4. 4

    DiMasi, J.A., Feldman, L., Seckler, A. & Wilson, A. Clin. Pharmacol. Ther. 87, 272–277 (2010).

  5. 5

    Gschwind, A., Fischer, O.M. & Ullrich, A. Nat. Rev. Cancer 4, 361–370 (2004).

  6. 6

    Sheridan, C. Nat. Biotechnol. 29, 121–128 (2011).

  7. 7

    Cockburn, I.H.R. Proc. Natl. Acad. Sci. USA 93, 12725–12730 (1996).

  8. 8

    Pisano, G.P. Science Business: the Promise, the Reality, and the Future of Biotech (Harvard Business School Press, Boston; 2006).

  9. 9

    Guedj, I. & Scharfstein, D. Organizational Scope and Investment: Evidence from the Drug Development Strategies of Biopharmaceutical Firms. NBER working paper 10933 (National Bureau of Economic Research, 2004).

Download references

Author information

Correspondence to Fred Ledley.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

McNamee, L., Ledley, F. Making the biotech IPO work. Nat Biotechnol 31, 969–970 (2013). https://doi.org/10.1038/nbt.2711

Download citation

Further reading